Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389756 | 0.93 | MAPT (0.45) | MAPTRAB9ASMN1; SMN2PDK2ALDH1A1 | |
| SCHEMBL12388982 | 0.89 | SRD5A2 (0.44) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12365277 | 0.87 | PDK2 (0.42) | MAPTRAB9ASMN1; SMN2PDK2NPC1 | |
| SCHEMBL12365278 | 0.84 | PTGS2 (0.45) | MAPTRAB9APDK2ALDH1A1HPGD | |
| SCHEMBL12389908 | 0.84 | HTR2B (0.47) | MAPTRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12390182 | 0.82 | SRD5A2 (0.46) | MAPTRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12389769 | 0.82 | CREBBP (0.40) | MAPTRAB9ASMN1; SMN2PDK2NPC1 | |
| SCHEMBL12390204 | 0.82 | BRD4 (0.47) | MAPTRAB9ASMN1; SMN2PDK2ALDH1A1 | |
| SCHEMBL12390109 | 0.82 | MAPK14 (0.40) | MAPTRAB9ASMN1; SMN2PDK2NPC1 | |
| SCHEMBL12389840 | 0.81 | MAPT (0.41) | MAPTRAB9ASMN1; SMN2PDK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPT 463/4885RAB9A 430/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.